» Articles » PMID: 38244120

Idiopathic Erythrocytosis: a Germline Disease?

Abstract

Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible underling germline or somatic cause. We demonstrated that most of our cohort (40/56: 71.4%) showed no evidence of clonal hematopoiesis, suggesting that IE is, in large part, a germline disorder. We identified 20 low mutation burden somatic variants (Variant allelic fraction, VAF, < 10%) in only 14 (25%) patients, principally involving DNMT3A and TET2. Only 2 patients presented high mutation burden somatic variants, involving DNMT3A, TET2, ASXL1 and WT1. We identified recurrent germline variants in 42 (75%) patients occurring mainly in JAK/STAT, Hypoxia and Iron metabolism pathways, among them: JAK3-V722I and HIF1A-P582S; a high fraction of patients (48.2%) resulted also mutated in homeostatic iron regulatory gene HFE-H63D or C282Y. By generating cellular models, we showed that JAK3-V722I causes activation of the JAK-STAT5 axis and upregulation of EPAS1/HIF2A, while HIF1A-P582S causes suppression of hepcidin mRNA synthesis, suggesting a major role for these variants in the onset of IE.

Citing Articles

Spotlight on amino acid changing mutations in the JAK-STAT pathway: from disease-specific mutation to general mutation databases.

Hoffmann M, Hennighausen L Sci Rep. 2025; 15(1):6202.

PMID: 39979591 PMC: 11842829. DOI: 10.1038/s41598-025-90788-5.


Impact of mutations on thrombotic risk in patients with idiopathic erythrocytosis: A single-centre study.

Bertozzi I, Benetti A, Cosi E, Zerbinati M, Fortino C, Randi M EJHaem. 2024; 5(5):1086-1088.

PMID: 39415931 PMC: 11474405. DOI: 10.1002/jha2.1019.

References
1.
Biagetti G, Catherwood M, Robson N, Bertozzi I, Cosi E, McMullin M . HFE mutations in idiopathic erythrocytosis. Br J Haematol. 2017; 181(2):270-272. DOI: 10.1111/bjh.14555. View

2.
Lee G, Arcasoy M . The clinical and laboratory evaluation of the patient with erythrocytosis. Eur J Intern Med. 2015; 26(5):297-302. DOI: 10.1016/j.ejim.2015.03.007. View

3.
Vannucchi A . From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica. 2016; 102(1):18-29. PMC: 5210229. DOI: 10.3324/haematol.2015.129155. View

4.
Alvarez-Larran A, Lopez-Guerra M, Rozman M, Correa J, Hernandez-Boluda J, Tormo M . Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Ann Hematol. 2019; 98(10):2319-2328. DOI: 10.1007/s00277-019-03766-z. View

5.
Torti L, Teofili L, Capodimonti S, Nuzzolo E, Iachininoto M, Massini G . Hypoxia-inducible factor-1α(Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors. Blood Transfus. 2013; 11(4):553-7. PMC: 3827400. DOI: 10.2450/2013.0076-13. View